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 ABSTRACT: The use of untargeted metabolomics for the discovery of markers is a promising and virtually unexplored 
tool in the doping control field. Hybrid quadrupole time-of-flight (QTOF) and hybrid quadrupole Orbitrap (Q Exactive) 
mass spectrometers, coupled to ultra-high pressure liquid chromatography are excellent tools for this purpose. In the pre-
sent work, QTOF and Q Exactive have been used to look for markers for testosterone cypionate misuse by means of un-
targeted metabolomics. Two different groups of urine samples were analyzed; collected before and after the intramuscu-
lar administration of testosterone cypionate. In order to avoid analyte losses in the sample treatment, samples were just 
two-fold diluted with water, and directly injected into the chromatographic system. Samples were analyzed in both posi-
tive and negative ionization modes. Data from both systems were treated under untargeted metabolomic strategies using 
XCMS application and multivariate analysis. Results from the two mass spectrometers differed in the number of detected 
features, but both led to the same potential marker for the particular testosterone ester misuse. The in-depth study of the 
MS and MS/MS behavior of this marker allowed for the establishment of 1-cyclopentenoylglycine as feasible structure. 
The putative structure was confirmed by comparison with synthesized material. This potential marker seems to come 
from the metabolism of the cypionic acid release after hydrolysis of the administered ester. Its suitability for doping con-
trol has been evaluated. 
 
1. INTRODUCTION 
Metabolomics is one of the most useful approaches for 
the discovery of new metabolites or markers. It consists of 
the comprehensive measurement of the low-molecular 
weight metabolites of a cell, tissue or body fluid, resulting 
from metabolic processes in organisms1. Large number of 
data is commonly obtained from analytical platforms 
based on mass spectrometry (MS) and Nuclear Magnetic 
Resonance (NMR). The selection of the instrumentation 
is an important issue since it is a key factor regarding the 
number of peaks detected and their sensitivity/specificity. 
Due to their high resolution, mass accuracy and full-
spectrum acquisition capabilities, high resolution (HR) 
mass analyzers such as Orbitrap, TOF or hybrids analyz-
ers like quadrupole-time of flight (QTOF) and quadrupole 
Orbitrap (Q Orbitrap) are adequate to develop metabolic 
profiling methods in complex biological matrices such as 
urine2-4. Profiling at metabolite levels or an individual’s 
 response to stimuli, environment or drug treatment are 
well described5; as well as other applications in food sci-
ences3,6, plant metabolomics7 and clinical research8,9 
among others. However, its implementation in other 
fields such as doping control is rather limited. 
The potential usefulness of metabolomics for doping 
control purposes is described on literature10-12, where it is 
illustrated that “omics” methods may be ideal platforms 
for the discovery of markers of the abuse of some prohib-
ited substances or methods for which the direct detection 
presents difficulties. This is the case of endogenous ana-
bolic androgenic steroids (EAAS) like testosterone (T). 
EAAS are responsible for the largest number of adverse 
analytical findings reported by doping control laborato-
ries13. EAAS are naturally present in humans, thus, the 
detection of the misuse of this group of compounds a 
challenging task. Ratio between urinary T and epitestos-
terone (E), both excreted as glucuronides (T/E), was first-
ly used to distinguish between natural and administrated 
testosterone by Donike et al. in 198314. This ratio provided 
a solution to screen for T misuse until it was found that 
people with a common deletion polymorphism in the 
UGT2B17 gene excreted low concentration of T, thus gen-
erating abnormally low T/E ratios even after testosterone 
administration15,16. Nowadays, the current strategy for the 
screening of EAAS is based on the quantification in every 
urine sample of the so-called steroid profile, i.e. seven 
markers related with T, and its inclusion in the Athlete 
Biological Passport17 (ABP). The discovery of alternative 
markers which might complement the steroid profile is 
currently an active research topic in the doping control 
field. Several alternative T metabolites have been pro-
posed for this purpose18,19. The application of target 
metabolomic approaches has been described as a useful 
tool for the selection of new markers20,21. Open detection 
methods, i.e. scan acquisition of the whole m/z range us-
ing high resolution mass spectrometry have been used for 
the differentiation of the metabolic profiles before and 
after testosterone administration12. However, the untar-
geted results were filtered by the expected m/z of T me-
tabolites and only the expected ones (metabolites coming 
from known pathways such as hydroxylation, reduction, 
oxidation and conjugation either with glucuronic acid or 
with sulfate) were considered for the ulterior statistical 
analysis. Although untargeted metabolomics has been 
used for the detection of pathways altered after the ad-
ministration of different doping agents22, its potential for 
the detection of alternative markers remains virtually 
unexplored in this field.   
The goal of the present study is to evaluate the poten-
tial of untargeted metabolomics in the doping control 
field, analyzing the differences and similarities between 
two systems: UHPLC-QTOF and UHPLC-QOrbitrap. By 
means of a metabolomic approach and using these power-
ful analytical techniques, markers of T misuse after T 
cypionate administration were investigated. The experi-
mental design aimed to detect those markers which can 
be detectable even several days after administration irre-
spective on the basal T/E values. 
 2. MATERIALS AND METHODS 
2.1. Reagents and chemicals 
For QTOF analysis, HPLC-grade water was obtained by 
purifying demineralised water in a Milli-Q plus system 
from Millipore (Bedford, MA, USA). HPLC-grade metha-
nol (MeOH), residue analysis grade acetone, sodium hy-
droxide (>99%) and formic acid (98-100%) were acquired 
from Scharlab (Barcelona, Spain). Leucine-Enkephalin, 
used as the lock mass, was purchased from Sigma Aldrich 
(St. Louis, MO, USA). 
In case of Q Orbitrap analysis, LC–MS grade methanol 
and LC–MS grade water were purchased from Biosolve 
(Valkenswaard, Netherlands). Formic acid Optima® 
LC/MS was purchased from Fischer Scientific (Loughbor-
ough, UK). Exactive Calibration Kit solutions employed 
were purchased from (Sigma–Aldrich, St. Louis, MO, USA 
and ABCR GmbH & Co. KG, Karlsruhe, Germany).  
For the synthesis of the 1- cyclopentenoylglycine (1-
CPG), 1-cyclopetenecarboxilic acid, glycine, benzyl chlo-
roformate, triethylamine and dimethyl sulfoxide (DMSO) 
were purchased from Sigma-Aldrich Química S.A. (Ma-
drid, Spain) and trifluoroacetic acid (TFA) was purchased 
from Carlo Erba Reagents (Barcelona, Spain). Finally, deu-
terated methanol (CD3OD) used in the NMR experiments 
was purchased from Euriso Top (Saint-Aubin, France). 
2.2. Instrumentation 
2.2.1 Xevo G2 QTOF  
Acquity ultra-performance liquid chromatography sys-
tem (Waters, Milford, MA, USA) was interfaced to a Xevo 
G2 QTOF mass spectrometer (Waters Micromass, Man-
chester, UK) using an orthogonal Z-spray electrospray 
(ESI) interface. The chromatographic separation was per-
formed using an Acquity UPLC BEH C18 column (1.7 µm, 
2.1 x 100 mm) from Waters, using a ﬂow rate of 0.3 
mL/min. The mobile phases used were (A) H2O and (B) 
MeOH, both with 0.01% (v/v) HCOOH. The percentage of 
MeOH was linearly increased as follows: 1 min, 2%; 3 min, 
15%; 6 min, 50%; 9 min, 95%; 10 min, 95%; 10.01 min, 2% 
and 12 min, 2%. The total run time was 12 min. The injec-
tion volume was 20 μL. Nitrogen (Praxair, Valencia, 
Spain) was used as both drying and nebulizig gas. The 
desolvation gas ﬂow rate was set at 1000 L/h. The resolu-
tion of the TOF mass spectrometer was ~20,000 at full 
width half maximum (FWHM) at m/z 556. MS data were 
acquired over a m/z range of 50–1000 with a scan time of 
0.4 s. Capillary voltages of 0.7 kV and 2.5 kV were used in 
positive and negative ionization modes, respectively. A 
cone voltage of 20 V was applied. Argon was used as colli-
sion gas (99.995%, Praxair). The interface temperature 
was set to 550 ºC and the source temperature to 130 ºC. 
The column temperature was set to 40 ºC and the au-
tosampler to 5 ºC. The same cone voltage and collision 
energy ramp was used for additional tandem MS (MS/MS) 
experiments. 
Calibration of the mass-axis and automated accurate 
mass measurement are described in supporting infor-
mation (Section S1). 
 2.2.2 Q-Exactive Orbitrap 
The liquid chromatographic system was an Accela LC 
(Thermo Scientific, Bremen, Germany) equipped with 
degasser, Accela 1250 pump, autosampler at 7 ºC and a 
heated column compartment at 40 ºC. The same column, 
injection volume, chromatographic conditions, mobile 
phases, flow rate and gradient employed in the QTOF 
system, were used in this instrument. The LC effluent was 
pumped to a Q-Exactive benchtop Orbitrap based mass 
spectrometer (Thermo Scientific, Bremen, Germany) op-
erating in the positive/negative polarity switching mode 
and equipped with an electrospray (ESI) source. Nitrogen 
sheath gas flow rate and auxiliary gas were set at 50 and 
20 (arbitrary units), respectively. The S-lens RF level was 
set at 100 (arbitrary units). The capillary temperature was 
250 ºC and the spray voltage 4 kV in both ion modes. The 
instrument operated in full spectrum acquisition from 
m/z 50 to 1000. The resolution was 35,000 (FWHM at m/z 
200) with a scan time of 0.45 s in polarity switching mode. 
The automatic gain control (AGC) was 106. Data were ac-
quired in centroid mode. The Q Orbitrap performance in 
both positive and negative ionization modes was daily 
evaluated daily and external calibration was daily done 
with Calibration Kit solutions.  
2.3. Administration study samples 
Eight healthy male volunteers were included in two T 
excretion studies (one performed in Spain and the other 
one in China). Four volunteers with T/E values between 1 
and 3 (coming from the first study) and four volunteers 
with T/E values below 0.3 (coming from the second one) 
were selected. Four basal urine samples (first morning 
urine) were collected, three of them during the three con-
secutive days before the administration (-72 h, -48 h and -
24 h) and, the other one, the day of the administration (0 
h). After the administration of a single dose of 100 mg of 
testosterone intramuscularly injected (Testex prolonga-
tum®, 1 vial of 2 mL containing  100 mg of testosterone 
cypionate, Desma Laboratorio Farmaceutico, Madrid, 
Spain), several samples were collected up to 15 days after 
administration. Samples were stored at -20 ºC until the 
analysis. 
Subjects signed an informed consent before participa-
tion. Both protocols were approved by the local Research 
Ethics Committees and authorized by the state authori-
ties. Both studies were conducted in accordance with the 
Declaration of Helsinki and state laws concerning clinical 
trials. Treatment was well tolerated by the subjects and 
no serious adverse events were observed.  
For the metabolomic study, urine samples before (4 
samples) and after administration (7 samples collected on 
days 1, 2, 3, 4, 5, 7 and 9) were considered for the analysis. 
A total of 32 pre-administration samples (4 per 8 volun-
teers) formed the group Control and 56 post-
administration samples (7 per 8 volunteers) formed the 
group Treated. 
2.4. General strategy 
The general 4-steps workflow followed during this work 
is described below and is summarized in Figure S1 (sup-
porting information).  
2.4.1.  Sample treatment and injection 
500 µL of HPLC-grade water were added to the same 
volume of urine samples. The diluted extracts were direct-
ly injected into the UHPLC-QTOF and Q-Exactive MS 
systems in both positive and negative ionization modes. 
Samples were randomly injected in order to avoid that the 
results might be affected by the instrumental drift. Quali-
ty control (QC) samples were prepared by a pool of all the 
extracts in order to be a good representation of all the 
samples. Firstly, 10 QCs were injected in order to stabilize 
the chromatographic system and then an additional QC 
sample was injected every 10 samples in order to check 
the stability and the robustness of the measurements.   
Gradient elution was optimized in the QTOF for both 
positive and negative ionization mode injections, focusing 
on a better separation of the visible peaks in the Base 
Peak Ion (BPI) chromatograms. 
2.4.2. Data pre-processing and multivariate analysis 
The raw data acquired by the UHPLC-QTOF MS with 
the MassLynx operating software (version 4.1, Waters) 
were converted to Common Data Format (CDF) files us-
ing the Databridge application (from MassLynx).  
Raw data acquired by the UHPLC-QOrbitrap MS with 
Xcalibur 2.2 were initially separated into positive and 
negative files and then converted into CDF files using a 
conversion option provided within the Xcalibur software. 
The CDF data from both instruments were pre-
processed in the same way using the XCMS free soft-
ware23. First, a peak picking centWave method was used 
to locate mass traces and then, continuous wavelet trans-
form (CWT) was applied to find chromatographic peaks 
(peak width = 5-20 s, S/N threshold = 10, ppm = 15). Then, 
a density grouping method was applied to align the reten-
tion times of peaks with the same exact mass in all sam-
ples. For this purpose, a cluster of “well behaved peaks”, 
present in all samples with stable intensities, were used to 
correct the rest from an initial band width of 5 s to 1 s, 
after 4 iterations. The peak list provided by XCMS was 
normalized using loess normalization method24 and then 
imported into the EZinfo software (Umetrics, Umea, Swe-
den) for multivariate analysis. Principal Component Anal-
ysis (PCA), Partial Least Squares-Discriminant Analysis 
(PLS-DA) and Orthogonal Partial Least Squares-
Discriminant Analysis (OPLS-DA) were evaluated after 
unit variance (UV) scaling to look for the potential mark-
ers. In the OPLS-DA, samples belonging to Control and 
Treated classes were used for comparison. 
2.4.3. Marker selection 
The S-Plots generated by OPLS-DA, were studied in or-
der to obtain a list of candidates. Points located at the top 
right or at the bottom left were studied in all cases, corre-
sponding to the best markers which increase or decrease, 
respectively, after T administration. Feasibility of the can-
 didates was evaluated based on their Variable Trend 
Plots, adequate abundances and peak shapes.  
2.4.4. Marker identification 
In order to elucidate the structure of the potential 
marker, both MS and MS/MS spectra were studied. The 
molecular formula of the marker was obtained by the use 
of the accurate mass measurements of the precursor ion. 
This information together with that obtained after colli-
sion-induced dissociation at different collision energies 
was used for establishing a feasible structure for the 
marker. Confirmation of the hypothesis was performed 
after synthesis of the proposed structure. 
2.5. Synthesis of 1-cyclopentenoylglycine (1-CPG) 
For the synthesis of 1-CPG, 30 mg of 1-
cyclopentenecarboxylic acid were dissolved in 0.5 mL of 
acetonitrile and 22 L of triethylamine were added. The 
solution was cooled to 4 ºC and 50 L of benzyl chlo-
roformate were added. The reaction was left to proceed 
for 24h under vigorous stirring at room temperature. Af-
ter that, the solvents were removed under vacuum and 
the residue was dissolved in 0.5 mL of DMSO that con-
tained 40 L of triethylamine. Then, 30 mg of glycine dis-
solved in 0.5 mL of water were added and the reaction 
was left to proceed for 24 h at room temperature. The 
HPLC purification of the product is detailed in the sup-
porting information (section S2). Finally, after solvent 
removal, 16 mg of product as white solid were obtained.  
The characterization of the final product was per-
formed by NMR on a Mercury 400 MHz spectrometer 
equipped with OneNMR ProTune system probe. The 
NMR experiments were performed in deuterated metha-
nol (CD3OD) and chemical shifts are reported in ppm 
relative to the residual non deuterated methanol (δ=3.31 
ppm for 1H-NMR and δ = 49 ppm for 13C-NMR).1H NMR 
(400 MHz, CD3OD) δ= 6.62 (m, 
1H), 3.95 (s, 2H), 2.58 
(ddq, J = 10.1, 4.5, 2.4 Hz, 2H), 2.51 (ddq, J = 10.4, 5.1, 2.6 
Hz, 2H), 2.00 (p, J = 7.6 Hz, 2H). 13C NMR (101 MHz, 
CD3OD) δ= 175.68, 169.34, 139.80, 41.34, 31.87, 33.66, 23.87. 
2.6. 1-CPG and T/E evaluation  
In order to show the potential applicability of 1-CPG for 
doping control purposes, it was qualitatively determined 
in all samples collected from two volunteers, with basal 
T/E values of 2.9 and 0.15 respectively. The analysis was 
based on a two fold dilution of the sample with acetic acid 
1 M and subsequent determination by LC-MS/MS with 
triple quadrupole analyzer using the transition 170  95. 
All the details about this determination can be found in 
the supporting information (section S3). 
For comparison purposes, the common marker T/E was 
determined in the same samples by gas chromatography 
coupled to mass spectrometry (GC-MS) as described 
elsewhere25. 
 
3. RESULTS AND DISCUSSION 
3.1. Sample treatment, data pre-processing and multi-
variate analysis 
A “Dilute-and-shoot” strategy was applied to the urine 
samples in order to minimize losses during sample prepa-
ration and because it is a low time-consuming26. 
Samples were divided into two groups. The first one 
(Control) contained all samples collected before admin-
istration and the second one (Treated) those collected 
after administration (from day 1 to day 9). In order to ex-
tract those markers which allow for the detection of T 
misuse for long periods irrespective of the basal T/E val-
ues, neither the time after administration nor the basal 
T/E value were considered into the data analysis. 
The obtained data were pre-processed by XCMS for au-
tomatic peak detection and retention time alignment, 
generating tables of possible markers for each sample 
given by m/z and retention time in seconds with the for-
mat MxxxTxxx (where Mxxx stands for m/z and Txxx for 
retention time). In the QTOF analysis, 9889 and 11910 
unique peaks were found in positive and negative ioniza-
tion modes, respectively, whereas these values decreased 
when using Q Orbitrap to 7451 and 5528, respectively. 
These features included isotopes, adducts, and/or in-
source fragments. The differences might be explained 
either by a potentially higher sensitivity of the QTOF or 
by the possible generation of a larger number of ad-
ducts/in-source fragments in the ESI interface of this ana-
lyzer.  
XCMS data were first normalized to take into account 
the drift of the instrument as well as differences in urine 
concentration due to differences in the excreted volume. 
After loess normalization, intensities were more stable in 
the samples, in both positive and negative ionization 
modes, as it can be seen in Figure S2, supporting infor-
mation. These normalized data were then analyzed by 
PCA to have a non-supervised visualization of the results 
(Figure S3, supporting information). 
The use of QCs in non-targeted metabolomics analysis 
can be considered equivalent to the use of standards in 
target analysis, and their importance is described in the 
literature27,28. The PCA analysis showed that QCs were 
just in the middle of the plot, which implies that they 
could be regarded as representative of all the samples. 
Additionally, discrimination between samples before and 
after T cypionate administration was clearly observed in 
PCA for QTOF data (Figure S3, supporting information). 
The next step was the application of a PLS-DA, a super-
vised method that takes into account class information. 
Both instruments showed good discrimination of the 
groups (before and after T administration) irrespective of 
the ionization mode used (Figure S4, supporting infor-
mation).  
Finally, an OPLS-DA was applied in order to enhance 
the differences between selected classes (Control and 
Treated). This algorithm is a powerful tool for the analysis 
of qualitative data structures. It consists in an extension 
of the previous PLS regression method which integrates 
an orthogonal signal correction filter29. In the generated 
S-plots (Figure 1 for Q Orbitrap and Figure S5 of support-
ing information for QTOF), points located at the top right 
 square correspond to the features that increase after T 
administration whereas points at the bottom left square 
represent those that decrease after T administration.  
3.2. Selection of the marker 
The list of the top five features for QTOF and Q Or-
bitrap of each ionization mode is shown in Table 1.  
The variable trend plots of all the candidates that in-
creased and decreased after T administration were evalu-
ated. Variable trend plots from Q Orbitrap candidates 
M170T305 and M333T230 are shown in Figure S5 (support-
ing information), where it can be observed the different 
behavior of two candidates with a p(corr) value of 0.60247 
and 0.36836, respectively. Features with the highest 
p(corr) and with suitable variable trend plot were selected 
as candidates. 
Due to their low p(corr), none of the features that de-
creased after T administration was found to be a relevant 
candidate (Table 1). Regarding the features which in-
creased after T cypionate administration, the use of Q 
Orbitrap revealed the presence of only one marker in 
each ionization mode whereas the use of QTOF was able 
to detect two and four markers in positive and negative 
modes, respectively. The two potential markers obtained 
by QTOF in positive ionization mode shared the same 
retention time (295 s) suggesting that both features were 
generated by the same compound. In negative ionization, 
the use of QTOF allowed for the detection of additional 
features with p(corr) values higher than 0.5 (Table 1).  
These results illustrate that the larger number of fea-
tures found by QTOF compared to Q Orbitrap seems to 
be related to both, a larger number of detected com-
pounds and higher in-source fragmentation/adduct for-
mation. 
Remarkably, the compound eluting at around 300 s was 
found by both instruments illustrating the suitability of 
both platforms for the detection of untargeted markers. 
This fact, together with the elevated p(corr), the adequate 
peak shape and the suitable variable trend plot advised 
for the selection of this compound as suitable marker. 
This marker was detected in both ionization modes with 
m/z 170 and m/z 168 in positive and negative modes, re-
spectively. In the case of QTOF, the feature M95T295 was 
also observed. This feature could be explained as an in-
source fragment generated from M170T295, considering 
the retention time match. This feature was not observed 
in the data obtained with the Q Orbitrap, most likely due 
to the different source designs.  
3.3. Structural elucidation of the potential marker 
The first step for the structural elucidation was to es-
tablish the molecular formula of the marker. For this pur-
pose, the exact masses of both protonated [M+H]+ and 
deprotonated [M-H]- ions were extracted from the infor-
mation processed by XCMS (Table 2). From the positive 
ionization data, an accurate mass of m/z 170.0818 was 
obtained for the marker, and  C8H12NO3 was established 
as possible elemental composition of [M+H]+ (mass error 
0 ppm). In negative mode, this marker showed an m/z 
168.0657 corresponding to C8H10NO3 (mass error of -2.4 
ppm). All taken together allowed for the establishment of 
C8H11NO3 as elemental composition for the marker. The 
ionization in both modes as [M+H]+ and [M-H]- suggested 
the simultaneous presence of an acidic and a basic moiety 
in the molecule. 
As a second step for structural elucidation, MS/MS ex-
periments were carried out at different collision energies 
in positive and negative ionization modes (Table 2). In 
positive, a predominant product ion at m/z 95.0493 was 
observed. This ion corresponded with the feature 
M95T295 observed in the QTOF, thus confirming that it 
was produced by in-source fragmentation. The elemental 
composition of this ion was C6H7O (mass error -4.2 ppm) 
and therefore, it was formed after the neutral loss of 
C2H5NO2. This formula matches with the amino acid gly-
cine suggesting that the marker is a conjugate with gly-
cine. This fact was in agreement with the ionization ob-
served in both modes. The formula of the ion at m/z 
95.0498 (C6H7O) had a double bond equivalent of 3.5 
which is indicative of the presence of 3 unsaturations. 
When increasing the collision energy, an extra loss of CO 
was observed (m/z 67.0543, C5H7 mass error -4.5 ppm) 
suggesting the presence of a carbonyl group close to the 
glycine. The resultant ion (C5H7) had a double bond 
equivalent of 2.5 indicative of the presence of either two 
double bonds or a double bond and a ring. In the last 
case, a cyclopentene moiety was the most feasible struc-
ture for the formula C5H7 owing to the stability of the 
five-member ring structure. 
In negative ionization mode, the product ion spectrum 
was dominated by a loss of CO2 (m/z 124.0758, C7H10NO 
mass error -3.2 ppm) (Table 2). These results were indica-
tive of a carboxylic acid moiety. 
Based on this information, 1-CPG was postulated as fea-
sible structure for the selected marker. 
3.4. Confirmation of the proposed structure 
The confirmation of the proposed structure was made 
by comparison of the product ion spectra of the selected 
marker with the synthesized 1-CPG. The results are shown 
in Figure 2. The product ion scan spectra in both ioniza-
tion modes and the retention times were identical. These 
results allowed for the ultimate confirmation of the iden-
tity of the marker. 
3.5. Significance of the marker and potential application 
The pathway behind the occurrence of 1-CPG in urine 
after T cypionate injection was studied and a proposal for 
the formation of this marker is shown in Figure 3. As a 
first step, the hydrolysis of T cypionate releases free T and 
cypionic acid. Similar to fatty acids, cypionic acid might 
undergo -oxidation as main metabolic pathway30. After 
activation, this pathway involves two main processes: 
firstly the formation of a conjugated double bond and 
secondly the oxidative breakdown of this double bond 
releasing acetyl-CoA. While linear fatty acids suffer se-
quential -oxidation reactions until their total degrada-
tion, the second -oxidation for cypionic acid is unable to 
produce acetyl-CoA due to its cyclic nature. Therefore the 
 degradation process is stopped after the formation of the 
second double bond. At this point, the 1-cyclopentenoyl-
CoA formed is conjugated with glycine. Conjugation with 
glycine is a common metabolic pathway preceding the 
urinary excretion of several acids like benzoic acid, 3-
indoleacrylic acid or acetylsalicylic acid31,32. 
The potential usefulness of 1-CPG for T cypionate 
screening misuse was also evaluated and compared with 
the common marker T/E (Figure 4).  
The screening of T misuse by the detection of an exog-
enous compound has obvious advantages since the mere 
presence of the marker is sufficient to detect a suspicious 
sample. A small peak was found in every basal sample at 
the expected retention time (Figure S7). That opens the 
possibility for 1-CPG to be endogenous. Further research 
is needed to confirm the endogenous nature of the mark-
er. 
Results showed around 50-fold increase of 1-CPG after T 
administration (Figures 4 and S2) which was substantially 
higher than the observed for T/E (7 fold). Since the meta-
bolic pathway involved in the excretion of 1-CPG does not 
contain any glucuronidation step, the occurrence of this 
marker is irrespective of the polymorphism in the 
UGT2B17 gene affecting the T/E excretion. Therefore, sim-
ilar differences were observed in both volunteers. 
Whereas T/E was back to basal levels 10-11 days after 
administration, 1-CPG responses were still elevated in the 
last sample analyzed. Therefore, the use of 1-CPG im-
proves the retrospectivity of the detection of T cypionate 
misuse. 
According to our data, the detection of urinary 1-CPG 
might be a suitable approach for the screening of T cypi-
onate misuse. 
However, the approach also shows limitations. The first 
one is the fact that other drugs are commercialized as 
cypionate esters and a similar pathway is expected to be 
present. Therefore, the urinary detection of 1-CPG is not 
specific of T cypionate misuse and its detection might be 
only useful as a screening strategy. A subsequent confir-
mation process via the currently applied gas chromatog-
raphy combustion isotope ratio mass spectrometry (GC-
C-IRMS) procedures is compulsory. This situation is com-
parable with the current strategy based on GC-MS(/MS) 
quantification of some EAAS for screening and ulterior 
confirmation by GC-C-IRMS. On the other hand, T is also 
commercialized as other esters, like undecanoate, 
decaoate, isocaproate, phenylpropionate, propionate or 
enanthate and the approach will be not suitable to detect 
them. Despite some limitations, untargeted metabolomics 
appears as a suitable tool for the in-depth study of poten-
tial specific markers for other T preparations. The ap-
proach presented in this work is innovative and opens 
new possibilities in the field of doping control analysis. It 
might complement the current screening for T misuse or 
the direct detection of T esters which had been proposed 
long ago as a way to screen for T abuse33,34. 
 
4. CONCLUSIONS 
The usefulness of untargeted metabolomics for doping 
control analysis has been evaluated. The selection of an 
adequate procedure, that is, sample treatment, and ana-
lytical and data-treatment parameters, is of great im-
portance in an untargeted strategy like that applied in 
this work.  A key aspect of sample treatment is the ab-
sence of preconcentration and clean-up steps, which al-
lows for the preservation of all analytes present in the 
sample. However, alternative markers at low concentra-
tion levels might be underestimated using this approach 
and they might be discovered only after previous pre-
concentration of the samples.  
Urine samples collected before and after T administra-
tion were correctly separated by multivariate methods, 
giving as a result the same marker of T misuse using two 
HRMS analyzers. Both instruments seemed equally effi-
cient for untargeted metabolomics and both were suitable 
for searching unknown compounds in the doping control 
field. These results evidenced the robustness of the meth-
odology applied in the present work.  
The strategy followed included the whole set of samples 
from all volunteers together and considered samples col-
lected up to 9 days after T cypionate administration with-
in the same group (Treated). Thus, only those markers 
which are not affected by individual metabolism and 
which were still detectable after long periods are picked 
out. The satisfactory results of this study open novel al-
ternatives in the data treatment for the discovery of new 
markers. On one hand, the comparison of samples of a 
single individual, might lead to the discovery of new 
markers to be included in the ABP. On the other hand, a 
comparison between samples collected before and just 
after administration would also reveal markers for short-
term administration. Additionally, it is worth to notice 
that the application of a similar approach to samples col-
lected after T administration in other forms (gel, oral) 
might reveal the presence of additional and suitable 
markers for the detection of this misuse.  
This study confirms the suitability of state-of-the-art 
MS instrumentation for the development of untargeted 
metabolomics in doping control analysis. The developed 
approach allows for the detection of possible markers 
with the common bottleneck of the structure identifica-
tion, a task that is facilitated by performing an in-depth 
study of the MS(/MS) fragmentation of the compound. 
Even so, there are still some challenges before the marker 
is ready to routine use. The most important is related 
with the specificity of the identified substance as marker 
for the doping agent misuse. The concentration of the 
ideal marker should vary after the administration of the 
doping agent irrespective of the administration form 
whereas it should remain constant under other hypothet-
ical situations (including the administration of non-
prohibited substances). More research is required to 
demonstrate the usefulness of the marker. Then, it might 
be added into currently screening methods in order to 
minimize the resources used by the laboratories. The im-
plementation of a new marker for doping control analysis 
 implies a long way in which untargeted metabolomics 
might be seen as the first step.  
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(a) (b) 
Figure 1. OPLS-DA S-Plot for Q Orbritrap in (a) positive 
ionization mode and (b) negative ionization mode. Signi-
 ficant markers (m/z and RT) are highlighted. See more 
information in Table 1. 
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Figure 2. Product ion spectra in both positive (top) and 
negative (bottom) ionization mode for (a) urinary marker 
M170T295 and (b) synthesized 1-CPG 
 
Testosterone cypionate
O
O
O
Hydrolysis
+
O
HO
Testosterone
Cypionic acid
Activation
O
CoASO
CoAS
CoAS
O
O
CoAS
OH
O
-oxidation
-oxidation CoAS
O
Conjugation
O
N
H
HO
O
1-cyclopentenoylglycine  
Figure 3. Proposed metabolic pathway involved in the 
urinary occurrence of 1-CPG after testosterone cypionate 
injection 
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(a) (b) 
Figure 4. Comparison of the excretion profile of 1-CPG 
compared with T/E in (a) volunteer with basal T/E = 2.9 
and (b) volunteer with basal T/E = 0.16. 
 
TABLES 
Table 1. Best features obtained from OPLS-DA S-Plot, 
in QTOF and Q Orbitrap in both ionization modes. 
*selected markers for study. M stands for m/z and T for 
retention time. 
 Increase after T  
administration (right) 
Decrease after T  
administration (left) 
Marker p(corr) Marker p(corr) 
Q
T
O
F
  P
O
S
IT
IV
E
 M95T295* 0,64951 M259T555 -0,43191 
M170T295* 0,62215 M228T456 -0,39339 
M951T542_1 0,4789 M511T554 -0,39040 
M994T542 0,47680 M227T456 -0,38987 
M951T542_2 0,47375 M283T274 -0,38928 
N
E
G
A
T
IV
E
 M249T380 0,78888 M192T217 -0,42053 
M168T295 0,77079 M422T355 -0,36789 
M369T381_1 0,74499 M286T422 -0,36677 
M367T381 0,53850 M457T544 -0,35284 
M371T381 0,38594 M451T448 -0,34879 
Q
 O
rb
it
ra
p
 
P
O
S
IT
IV
E
 M170T305* 0,60247 M265T42 -0,40982 
M333T230 0,36836 M127T59 -0,38174 
M114T238 0,35049 M132T73 -0,35674 
M183T31 0,34885 M138T107 -0,35498 
M85T39 0,34856 M328T358 -0,35203 
N
E
G
A
T
IV
E
 M168T305* 0,67447 M123T287 -0,38195 
M165T23 0,41701 M151T355 -0,36366 
M501T563 0,39021 M279T575 -0,35547 
M215T65 0,35798 M229T510 -0,33049 
M373T517 0,35584 M179T463 -0,33011 
 
Table 2. Full scan and product ion scan information of 
the selected marker for QTOF  
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S
ca
n
 
Ionization Marker 
Accurate 
mass 
Error 
(ppm) 
Formula 
ESI+ M170T295 170.0817 0 C8H12NO3 
ESI- M168T295 168.0657 -2.4 C8H10NO3 
Ionization 
Marker 
(CE eV) 
Product 
ion 
(m/z) 
Error 
(ppm) 
Formula 
P
ro
d
u
ct
 
io
n
 s
ca
n
 ESI+ 
M170T295 
(20) 
95.0493 -4.2 C6H7O 
67.0543 -4.5 C5H7 
ESI- 
M168T295 
(20) 
124.0758 -3.2 C7H10NO 
96.0472 23.9 C5H6NO 
67.0547 -1.5 C5H7 
67.0562 
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